Foghorn TherapeuticsFHTX
FHTX
About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Employees: 112
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
167% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 12
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
9% more funds holding
Funds holding: 79 [Q3] → 86 (+7) [Q4]
0.11% more ownership
Funds ownership: 72.29% [Q3] → 72.39% (+0.11%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
49% less capital invested
Capital invested by funds: $372M [Q3] → $190M (-$182M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
114%
upside
Avg. target
$11.67
178%
upside
High target
$13
210%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Silvan Tuerkcan 20% 1-year accuracy 10 / 51 met price target | 114%upside $9 | Market Outperform Reiterated | 30 Apr 2025 |
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 15 / 53 met price target | 210%upside $13 | Buy Reiterated | 30 Apr 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target | 210%upside $13 | Buy Reiterated | 7 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Neutral
GlobeNewsWire
2 weeks ago
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population
Neutral
GlobeNewsWire
1 month ago
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Negative
Zacks Investment Research
1 month ago
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.57 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Negative
Zacks Investment Research
2 months ago
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
2 months ago
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Positive
Zacks Investment Research
2 months ago
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Negative
Zacks Investment Research
3 months ago
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Foghorn Therapeutics (FHTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
3 months ago
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Charts implemented using Lightweight Charts™